Comprehensive registry of lymphoproliferative disorders and outcomes
A Comprehensive Register Of Lymphoproliferative Disorders (ReLy)
This project will test how treatments, patient health, and genetic features affect 10-year survival in adults with lymphoproliferative disorders.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 9000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Fondazione IRCCS Policlinico San Matteo di Pavia Academic / other |
| Locations | 1 site (Pavia, Lombardy) |
| Trial ID | NCT07519356 on ClinicalTrials.gov |
What this trial studies
This observational registry enrolls adults with lymphoproliferative disorders, collecting retrospective and prospective clinical, treatment, and outcome data with long-term follow-up. The primary outcome is 10-year overall survival, and secondary objectives include documenting comorbidities, fitness, treatment choices, adverse events (including tumor lysis syndrome), and effectiveness of newer therapies such as chemo-free regimens, targeted drugs, and cell therapies. Investigators will correlate clinical and biological factors, including genotype and phenotype, with progression, relapse, and treatment discontinuation to identify optimal treatment sequences for relapsed or refractory cases. The registry is conducted at Fondazione IRCCS Policlinico San Matteo in Pavia, Lombardy, and aims to compare real-world effectiveness and safety across therapies.
Who should consider this trial
Good fit: Adults (age ≥18) diagnosed with or treated for lymphoproliferative disorders who can provide informed consent, or whose data are covered by institutional consent for retrospective inclusion, are eligible.
Not a fit: Patients seeking direct therapeutic benefit may not gain immediate medical benefit because this is an observational data registry, and those unable to provide informed consent are excluded.
Why it matters
Potential benefit: If successful, the registry could help doctors choose safer, more effective treatment sequences and improve long-term outcomes for patients.
How similar studies have performed: Other national and international lymphoma registries have improved understanding of outcomes and treatment patterns, but comprehensive integration of genotype data with newer targeted and cell therapies and treatment-sequence analysis remains relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients ≥ 18 years diagnosed with and/or treated for lymphoproliferative disorders. * Prospective patients (or their or legal guardians) who have the ability to understand and be willing to sign a written informed consent document * Retrospective patients who have signed the institutional document allowing the use of their data for research on their disease Exclusion Criteria: * Patients who are unable to understand informed consent document
Where this trial is running
Pavia, Lombardy
- Fondazione IRCCS Policlinico San Matteo — Pavia, Lombardy, Italy (Recruiting)
Study contacts
- Study coordinator: Luca Arcaini
- Email: l.arcaini@smatteo.pv.it
- Phone: 0382501284
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.